SCHEMBL354055

SCHEMBL354055

C1OC1CN1CCN(CC2CO2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
HBB P68871 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADRA1A P35348 2/20 0.34
ADRA2C P18825 2/20 0.34
GAA P10253 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1B P35368 1/20 0.34
SCN1A P35498 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN3A Q9NY46 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
HTR1A P08908 1/20 0.34
MAPT P10636 1/20 0.33
DHFR P00374 1/20 0.33
TMEM97 Q5BJF2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16274766 0.92 TP53 (0.42) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL3360174 0.87 HRH3 (0.42) TP53HBBSMN1; SMN2TDP1ADRA1A
SCHEMBL10319412 0.87 CHRM5 (0.44) TP53HBBSMN1; SMN2ADRA2CSCN1A
SCHEMBL3357474 0.86 ADRA2C (0.48) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL6577437 0.86 ADRA2C (0.48) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL18638043 0.86 ADRA2C (0.48) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL21915928 0.86 ADRA2C (0.48) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL18638041 0.86 ADRA2C (0.48) TP53HBBSMN1; SMN2ALDH1A1TDP1
SCHEMBL336214 0.84 GAA (0.50) TP53HBBSMN1; SMN2ALDH1A1GAA
SCHEMBL13415572 0.84 GAA (0.50) TP53HBBSMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4032482-A FROM A POLY-N-SUBSTITUTED POLYAMINE OR POLYALKYLENIMINE-EPOXY COMPOUND PREPOLYMER MIYOSHI YUSHI KABUSHIKI KAISHA (JA) 1977-06-28 US claimed
US-4026831-A ADHESIVES, PAINT RESINS, ELECTROSTATIC INHIBITORS, RUST INHIBITORS MIYOSHI YUSHI KABUSHIKI KAISHA (JA) 1977-05-31 US claimed
US-12583876-B2 Branched organosilicon compound, method of preparing same, and related compositions DOW SILICONES CORPORATION (US) 2026-03-24 US disclosed
US-12533401-B2 Devices and methods for modulating ADMA in blood THE TRUSTEES OF INDIANA UNIVERSITY (US) 2026-01-27 US disclosed
EP-3493878-B1 COSMETIC COMPOSITION COMPRISING CURED SILICONE MATERIALS DOW SILICONES CORP (US) 2025-10-08 EP disclosed
US-12398270-B2 Acrylate-functional branched organosilicon compound, method of preparing same, and copolymer formed therewith DOW SILICONES CORPORATION (US) 2025-08-26 US disclosed
US-12371211-B2 Packaging solutions BAUSCH + LOMB IRELAND LIMITED (IE) 2025-07-29 US disclosed
US-12371535-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith DOW SILICONES CORPORATION (US) 2025-07-29 US disclosed
US-12338259-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith DOW SILICONES CORPORATION (US) 2025-06-24 US disclosed
US-20250154289-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2025-05-15 US disclosed
EP-4540297-A1 PHOTOCURABLE COMPOSITIONS AND METHODS FOR DELIVERING RADIATION TO A SUBJECT Theragenics Corporation (US) 2025-04-23 EP disclosed
US-4308085-A Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts JENOPTIK JENA GMBH (DD) 1981-12-29 US disclosed
US-4305829-A Process for flocculating an aqueous suspension of particles with quaternary ammonium graft copolymers UNION CARBIDE CORPORATION (US) 1981-12-15 US disclosed
US-4277566-A REMOVING HEAVY METALS FROM WASTE WATERS OR RECOVERING THEM FROM SEA WATER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-07-07 US disclosed
US-4271053-A PREPARED FROM A DIAMINE AND AN EPIHALOHYDRIN OR A DIEPOXIDE UNION CARBIDE CORPORATION (US) 1981-06-02 US disclosed
US-4240450-A HAIR CONDITIONER OF ANIONIC POLYMERS AND CATIONIC POLYMERS L'OREAL (FR) 1980-12-23 US disclosed
US-4228259-A FROM A POLYAMINO-AMIDE AND A CHROMOPHORE OR CHROMOGEN GROUP L'OREAL (FR) 1980-10-14 US disclosed
US-4032482-A FROM A POLY-N-SUBSTITUTED POLYAMINE OR POLYALKYLENIMINE-EPOXY COMPOUND PREPOLYMER MIYOSHI YUSHI KABUSHIKI KAISHA (JA) 1977-06-28 US disclosed
US-4026831-A ADHESIVES, PAINT RESINS, ELECTROSTATIC INHIBITORS, RUST INHIBITORS MIYOSHI YUSHI KABUSHIKI KAISHA (JA) 1977-05-31 US disclosed
US-4013787-A CATIONIC POLYMERS SOCIETE ANONYME DITE: L'OREAL (FR) 1977-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154289-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT6 TP53 4198/4885HBB 2352/4885SMN1; SMN2 4684/4885
US-12583876-B2 Branched organosilicon compound, method of preparing same, and related compositions OXSR1, BRS3, NPSR1 TP53 3521/4885HBB 2750/4885SMN1; SMN2 2283/4885
US-12338259-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith OXSR1, BRS3, ORC3 TP53 3179/4885HBB 2676/4885SMN1; SMN2 1443/4885
US-12533401-B2 Devices and methods for modulating ADMA in blood ADM2, PADI1, DDAH1 TP53 3339/4885HBB 1137/4885SMN1; SMN2 1197/4885
US-12371535-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith OXSR1, BRS3, OXER1 TP53 3175/4885HBB 2999/4885SMN1; SMN2 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.